Report
EUR 13.79 For Business Accounts Only

YPSOMED HOLDING AG sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of YPSOMED HOLDING AG (CH), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 22, 2022, the closing price was CHF 166.80 and its potential was estimated at CHF 182.76.
Underlying
Ypsomed Holding AG

Ypsomed Holding operates in the field of medical technology and is an independent manufacturer of injection pens for pharmaceutical and biotech companies. Additionally, Co. supplies pen needles. Co.'s core business consists of developing and marketing products and services allowing patients to administer their own medication, in particular diabetes patients. Co. distributes its products worldwide by pharma and biotech companies under their own brand names. Co. operates production sites in Burgdorf, Solothurn, Grenchen and Tabor and has a sales and distribution network across Europe.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch